Current perspectives on novel systemic therapeutic agents beyond immune checkpoint inhibition in metastatic urothelial carcinoma

Treatment strategies for metastatic urothelial carcinoma (mUC) have evolved dramatically over the last decade. The emergence of immunotherapeutic agents, especially immune checkpoint inhibitors, has been the most significant development. Immunotherapy increased the overall survival rate of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hoon, Park, Jae Young, Bae, Jae Hyun, Tae, Bum Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Urothelial Carcinoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799034/
https://www.ncbi.nlm.nih.gov/pubmed/35117268
http://dx.doi.org/10.21037/tcr-20-1262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799034/
https://www.ncbi.nlm.nih.gov/pubmed/35117268
http://dx.doi.org/10.21037/tcr-20-1262

Ejemplares similares